ArticleCureus2026
Genetic Mutations and Clinical Severity in Hemoglobin E/Beta-Thalassemia Patients in Bangladesh.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective The phenotypically diverse presentation of hemoglobin (Hb) E/β-thalassemia is often attributed to coinheritance of β-globin (HBB) gene mutations. This study aimed to describe the genetic mutations and clinical severity of HbE/β-thalassemia patients from low-resource settings. Methods A total of 32 HbE/β-thalassemia patients were included in this cross-sectional study. Cases were confirmed by capillary Hb electrophoresis or high-performance liquid chromatography and were further analyzed alongside clinical information and ancestral data. The data collection period spanned from May 2019 to July 2020. Gene sequencing was performed using the Sanger sequencing method for mutational analysis, and Mahidol scoring was applied to assess clinical severity. Results The median age of the patients was 20 years (interquartile range (IQR): 17-22.5). Phenotypically, mild, moderate, and severe disease were observed in 12 (37.5%), 14 (43.8%), and six (18.8%) patients, respectively. Overall, 13 heterozygous mutations were identified in the HBB gene. Among these, IVS-1-5 (G>C) was the most common mutation (n = 17, 53.1%), and codon 30 (G>C) (n = 4, 12.5%) was the second most common mutation. The IVS-1-5 (G>C) mutation was significantly more frequent among patients with severe disease (p<0.001). Conclusions This study is one of the few to characterize clinical severity and genetic mutations in HbE/β-thalassemia patients in Bangladesh. The information on clinical severity patterns could be useful for determining service priorities and ensuring the proper allocation of limited resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.